Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Published:2020-06-16 Issue:9 Volume:61 Page:2103-2112
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Coyle Luke¹,Morley Nicholas J.²,Rambaldi Alessandro³,Mason Kylie D.⁴,Verhoef Gregor⁵,Furness Caroline L.⁶,Zhang Alicia⁷,Jung A. Scott⁸,Cohan David⁸,Franklin Janet L.⁸

Affiliation:

1. Department of Haematology, Royal North Shore Hospital, St. Leonards, Australia;

2. Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK;

3. Department of Oncology-Hematology, University of Milan and Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy;

4. Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia;

5. Department of Hematology, UZ Leuven, University Hospitals Leuven, Leuven, Belgium;

6. Department of Paediatric Haemato-Oncology, Royal Marsden NHS Foundation Trust, London, UK;

7. Global Biostatistical Science, Amgen Inc, Thousand Oaks, CA, USA;

8. Global Development, Amgen Inc, Thousand Oaks, CA, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1759055

Reference25 articles.

1. Diffuse large B-cell lymphoma: R-CHOP failure—what to do?

2. Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12

3. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

4. Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

5. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T-Cell Engagers—The Structure and Functional Principle and Application in Hematological Malignancies;Cancers;2024-04-20

2. Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison;Molecular Cancer;2024-04-16

3. New immune cell engagers for cancer immunotherapy;Nature Reviews Immunology;2024-01-25

4. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

5. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma;Blood Reviews;2024-01